Erik Thunnissen

Erik Thunnissen

Auto-generated profile, based on publicly available information

Erik Thunnissen

Department of Pathology, Amsterdam University Medical Center, VU University Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2011 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
WTWilliam D. Travis
William D. Travis
EBElisabeth Brambilla
Elisabeth Brambilla
MNMasayuki Noguchi
Masayuki Noguchi
ANAndrew G. Nicholson
Andrew G. Nicholson
KGKim R. Geisinger
Kim R. Geisinger
DYDavid Yankelewitz
David Yankelewitz

2 September 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MPMartin Peifer
Martin Peifer
LFLynnette Fernández-Cuesta
Lynnette Fernández-Cuesta
MSMartin L Sos
Martin L Sos
JGJulie George
Julie George
DSDanila Seidel
Danila Seidel
RTRoman K Thomas
Roman K Thomas

15 December 2010 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JWJonathan Weiss
Jonathan Weiss
MSMartin L. Sos
Martin L. Sos
DSDanila Seidel
Danila Seidel
MPMartin Peifer
Martin Peifer
TZThomas Zander
Thomas Zander
RTRoman K. Thomas
Roman K. Thomas
FGFR1 amplification provides a therapeutic target for squamous cell lung cancer, which is resistant to other targeted lung cancer drugs.

3 December 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
RKRob J. van Klaveren
Rob J. van Klaveren
MOMatthijs Oudkerk
Matthijs Oudkerk
MPMathias Prokop
Mathias Prokop
ESErnst T. Scholten
Ernst T. Scholten
KNKristiaan Nackaerts
Kristiaan Nackaerts
HKHarry J. de Koning
Harry J. de Koning
The use of multidetector computed tomography (CT) in lung-cancer screening trials involving subjects with an increased risk of lung cancer has highlighted the problem for the clinician of deciding on the best course of action when noncalcified pulmonary nodules are detected by CT. A total of 7557 participants underwent CT screening in years 1, 2, and 4 of a randomized trial of lung-cancer screening. We used software to evaluate a noncalcified nodule according to its volume or volume-doubling time. Growth was defined as an increase in volume of at least 25% between two scans. The first-round screening test was considered to be negative if the volume of a nodule was less than 50 mm3, if it was 50 to 500 mm3 but had not grown by the time of the 3-month follow-up CT, or if, in the case of those that had grown, the volume-doubling time was 400 days or more. In the first and second rounds of screening, 2.6% and 1.8% of the participants, respectively, had a positive test result. In round one, the sensitivity of the screen was 94.6% (95% confidence interval [CI], 86.5 to 98.0) and the negative predictive value 99.9% (95% CI, 99.9 to 100.0). In the 7361 subjects with a negative screening result in round one, 20 lung cancers were detected after 2 years of follow-up. Among subjects at high risk for lung cancer who were screened in three rounds of CT scanning and in whom noncalcified pulmonary nodules were evaluated according to volume and volume-doubling time, the chances of finding lung cancer 1 and 2 years after a negative first-round test were 1 in 1000 and 3 in 1000, respectively. (Current Controlled Trials number, ISRCTN63545820.)

1 July 2013 in The Journal of Molecular Diagnostics
Verified
Journal Article
Open access
NLNeal I. Lindeman
Neal I. Lindeman
PCPhilip T. Cagle
Philip T. Cagle
MBMary Beth Beasley
Mary Beth Beasley
DCDhananjay Arun Chitale
Dhananjay Arun Chitale
SDSanja Dacic
Sanja Dacic
MLMarc Ladanyi
Marc Ladanyi
To establish evidence-based recommendations for the molecular analysis of lung cancers that are required to guide EGFR- and ALK-directed therapies, addressing which patients and samples should be tested, and when and how testing should be performed. Three cochairs without conflicts of interest were selected, one from each of the 3 sponsoring professional societies: College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Writing and advisory panels were constituted from additional experts from these societies. Three unbiased literature searches of electronic databases were performed to capture published articles from January 2004 through February 2012, yielding 1533 articles whose abstracts were screened to identify 521 pertinent articles that were then reviewed in detail for their relevance to the recommendations. EVIDENCE was formally graded for each recommendation. Initial recommendations were formulated by the cochairs and panel members at a public meeting. Each guideline section was assigned to at least 2 panelists. Drafts were circulated to the writing panel (version 1), advisory panel (version 2), and the public (version 3) before submission (version 4). The 37 guideline items address 14 subjects, including 15 recommendations (evidence grade A/B). The major recommendations are to use testing for EGFR mutations and ALK fusions to guide patient selection for therapy with an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitor, respectively, in all patients with advanced-stage adenocarcinoma, regardless of sex, race, smoking history, or other clinical risk factors, and to prioritize EGFR and ALK testing over other molecular predictive tests. As scientific discoveries and clinical practice outpace the completion of randomized clinical trials, evidence-based guidelines developed by expert practitioners are vital for communicating emerging clinical standards. Already, new treatments targeting genetic alterations in other, less common driver oncogenes are being evaluated in lung cancer, and testing for these may be addressed in future versions of these guidelines.

1 June 2013 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Open access
PDF file
NLNeal I. Lindeman
Neal I. Lindeman
PCPhilip T. Cagle
Philip T. Cagle
MBMary Beth Beasley
Mary Beth Beasley
DCDhananjay Arun Chitale
Dhananjay Arun Chitale
SDSanja Dacic
Sanja Dacic
MLMarc Ladanyi
Marc Ladanyi
Objective.—To establish evidence-based recommendations for the molecular analysis of lung cancers that are required to guide EGFR - and ALK -directed therapies, addressing which patients and samples should be tested, and when and how testing should be performed. Participants .—Three cochairs without conflicts of interest were selected, one from each of the 3 sponsoring professional societies: College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Writing and advisory panels were constituted from additional experts from these societies. Evidence .—Three unbiased literature searches of electronic databases were performed to capture articles published from January 2004 through February 2012, yielding 1533 articles whose abstracts were screened to identify 521 pertinent articles that were then reviewed in detail for their relevance to the recommendations. Evidence was formally graded for each recommendation. Consensus Process .—Initial recommendations were formulated by the cochairs and panel members at a public meeting. Each guideline section was assigned to at least 2 panelists. Drafts were circulated to the writing panel (version 1), advisory panel (version 2), and the public (version 3) before submission (version 4). Conclusions .—The 37 guideline items address 14 subjects, including 15 recommendations (evidence grade A/B). The major recommendations are to use testing for EGFR mutations and ALK fusions to guide patient selection for therapy with an epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitor, respectively, in all patients with advanced-stage adenocarcinoma, regardless of sex, race, smoking history, or other clinical risk factors, and to prioritize EGFR and ALK testing over other molecular predictive tests. As scientific discoveries and clinical practice outpace the completion of randomized clinical trials, evidence-based guidelines developed by expert practitioners are vital for communicating emerging clinical standards. Already, new treatments targeting genetic alterations in other, less common driver oncogenes are being evaluated in lung cancer, and testing for these may be addressed in future versions of these guidelines.